This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Bromfenac sodium ocular

Updated 2 Feb 2023 | Ocular peri-operative drugs


Eye drops containing bromfenac as sodium sesquihydrate (preservative containing)

Drugs List

  • bromfenac 900microgram/ml eye drops
  • YELLOX 900microgram/ml eye drops
  • Therapeutic Indications


    Postoperative inflammation after cataract surgery



    Instil one drop into the affected eye(s) twice a day, starting the day after cataract surgery and continuing through the first 2 weeks of the postoperative period.

    The treatment period should not exceed two weeks.


    Instil one drop into the affected eye(s) twice a day, starting the day after cataract surgery and continuing through the first 2 weeks of the postoperative period.

    The treatment period should not exceed 2 weeks.


    Children under 18 years
    Wearing of contact lenses
    Third trimester of pregnancy

    Precautions and Warnings

    Predisposition to haemorrhage
    Corneal disorder
    Dry eyes
    First trimester of pregnancy
    Ocular infection
    Second trimester of pregnancy

    May impair healing or mask infection
    Advise patient blurred vision may affect ability to drive/operate machinery
    Contains benzalkonium chloride
    In combined therapy, administer eye products at least five minutes apart
    To reduce systemic absorption compress lacrimal sac during administration
    Monitor for, and discontinue in, corneal epithelial breakdown
    Not recommended for use longer than 2 weeks
    Advise patient to avoid touching the eye/other surfaces with container tip
    Discolours soft contact lenses
    Not to be used with contact lenses
    Remove contact lenses before use and re-insert 15 minutes after use

    The CSM have warned, in relation to oral NSAIDs, that any degree of worsening of asthma may be related to the ingestion of NSAIDs.

    Pregnancy and Lactation


    Bromfenac is contraindicated in the third trimester of pregnancy.

    Use bromfenac with caution in the first and second trimesters of pregnancy.

    NSAIDs (given systemically) are often discontinued in women failing to conceive although their role in inhibition of ovulation and in miscarriage is still being debated (Schaefer 2007). Studies have shown an increase in spontaneous abortion with the use of NSAIDs in early pregnancy (Briggs 2008). Discontinue if patient is attempting to become pregnant.

    Bromfenac sodium is a prostaglandin synthetase inhibitor and may have the following effects during the 2nd and 3rd trimesters:
    - Pulmonary and cardiac toxicity in the foetus (pulmonary hypertension with preterm closing of the ductus arteriosus). The risk exists from the beginning of the 6th month and increases if administration is close to full term.
    - Functional renal injury in the foetus. From the 12th week: oligohydramnios (usually reversible after the end of treatment) or anuria (particularly with prolonged exposure). Following birth, renal failure may persist (especially with late and prolonged exposure).
    - Inhibition of uterine contractions with delayed onset and prolongation of labour.
    - Increased possibility of bleeding in mother and child.
    - Increased risk of oedema formation for the mother.

    No reports describing bromfenac use during human pregnancy have been found, to date.

    In animal studies, doses of 900 times the recommended ophthalmic dose (given orally in rats) caused embryo foetal lethality, increased neonatal mortality and reduced postnatal growth. In rabbits, doses of 7500 times the recommended ophthalmic dose (given orally) caused increased post-implantation loss.

    It is not known if bromfenac crosses the placenta, though if present in maternal circulation, its low molecular weight makes this possible. The manufacturer states that systemic exposure is negligible (amount not specified).

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Bromfenac is considered safe for use in breastfeeding.

    The manufacturer of bromfenac sodium eye drops indicates that bromfenac is excreted in rat breast milk (following oral administration of high doses). It is not known if it is excreted in human breast milk. No adverse effects on the infant are anticipated at therapeutic doses and bromfenac eyed drops may be used during breast feeding.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Abnormal sensation in eye
    Allergic reaction
    Anaphylactic reaction
    Blurred vision
    Conjunctival hyperaemia
    Corneal disorders
    Corneal epithelium defect
    Corneal epithelium disorder
    Corneal erosion
    Corneal infiltrates
    Corneal oedema
    Corneal or scleral malacia
    Corneal perforation
    Corneal scar
    Corneal ulcer
    Dry eyes
    Eye irritation
    Eye pain
    Eye pruritus
    Eyelid bleeding
    Eyelid oedema
    Facial swelling
    Haemorrhagic retinopathy
    Ocular discharge
    Ocular discomfort
    Reddening of eyes
    Reduced visual acuity
    Retinal exudates
    Runny nose
    Tear film composition changes


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: July 2015

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Joint Formulary Committee. British National Formulary(online) London: BMJ Group and Pharmaceutical Press. Accessed on 06 July 2015.

    Summary of Product Characteristics: Yellox 0.9 mg/ml Eye Drops, Solution. Bausch & Lomb UK Ltd. Revised October 2020.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.